Deals in Depth: November 2010
Executive Summary
Surprisingly no Big Pharmas or top biotech companies were party to the biggest alliances. Instead German drug maker Grunenthal won out, selling its oral contraceptives portfolio to Gedeon Richter for $331 million. Both valued at $800 million, Lilly's acquisition of Avid ($300 million up front plus $500 million in earn-outs) and Medtronic's takeover of Ardian tied for the top spots in the M&A category. FOPOs were the most lucrative vehicle in pharma and device fundraising, with each industry bringing in over $200 million from this financing type.
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.